2025-02-012026-01-312026-01-31false15383230LIR THERAPEUTICS LIMITED2026-09-0272110falseiso4217:GBPxbrli:pure153832302025-01-31153832302026-01-31153832302025-02-012026-01-31153832302024-01-02153832302025-01-31153832302024-01-032025-01-3115383230bus:SmallEntities2025-02-012026-01-3115383230bus:AuditExempt-NoAccountantsReport2025-02-012026-01-3115383230bus:FullAccounts2025-02-012026-01-3115383230bus:PrivateLimitedCompanyLtd2025-02-012026-01-3115383230core:WithinOneYear2026-01-3115383230core:AfterOneYear2026-01-3115383230core:WithinOneYear2025-01-3115383230core:AfterOneYear2025-01-3115383230core:ShareCapital2026-01-3115383230core:SharePremium2026-01-3115383230core:RevaluationReserve2026-01-3115383230core:OtherReservesSubtotal2026-01-3115383230core:RetainedEarningsAccumulatedLosses2026-01-3115383230core:ShareCapital2025-01-3115383230core:SharePremium2025-01-3115383230core:RevaluationReserve2025-01-3115383230core:OtherReservesSubtotal2025-01-3115383230core:RetainedEarningsAccumulatedLosses2025-01-3115383230core:LandBuildings2026-01-3115383230core:PlantMachinery2026-01-3115383230core:Vehicles2026-01-3115383230core:FurnitureFittings2026-01-3115383230core:OfficeEquipment2026-01-3115383230core:NetGoodwill2026-01-3115383230core:IntangibleAssetsOtherThanGoodwill2026-01-3115383230core:ListedExchangeTraded2026-01-3115383230core:UnlistedNon-exchangeTraded2026-01-3115383230core:LandBuildings2025-01-3115383230core:PlantMachinery2025-01-3115383230core:Vehicles2025-01-3115383230core:FurnitureFittings2025-01-3115383230core:OfficeEquipment2025-01-3115383230core:NetGoodwill2025-01-3115383230core:IntangibleAssetsOtherThanGoodwill2025-01-3115383230core:ListedExchangeTraded2025-01-3115383230core:UnlistedNon-exchangeTraded2025-01-3115383230core:LandBuildings2025-02-012026-01-3115383230core:PlantMachinery2025-02-012026-01-3115383230core:Vehicles2025-02-012026-01-3115383230core:FurnitureFittings2025-02-012026-01-3115383230core:OfficeEquipment2025-02-012026-01-3115383230core:NetGoodwill2025-02-012026-01-3115383230core:IntangibleAssetsOtherThanGoodwill2025-02-012026-01-3115383230core:ListedExchangeTraded2025-02-012026-01-3115383230core:UnlistedNon-exchangeTraded2025-02-012026-01-3115383230core:MoreThanFiveYears2025-02-012026-01-3115383230core:Non-currentFinancialInstruments2026-01-3115383230core:Non-currentFinancialInstruments2025-01-3115383230dpl:CostSales2025-02-012026-01-3115383230dpl:DistributionCosts2025-02-012026-01-3115383230core:LandBuildings2025-02-012026-01-3115383230core:PlantMachinery2025-02-012026-01-3115383230core:Vehicles2025-02-012026-01-3115383230core:FurnitureFittings2025-02-012026-01-3115383230core:OfficeEquipment2025-02-012026-01-3115383230dpl:AdministrativeExpenses2025-02-012026-01-3115383230core:NetGoodwill2025-02-012026-01-3115383230core:IntangibleAssetsOtherThanGoodwill2025-02-012026-01-3115383230dpl:GroupUndertakings2025-02-012026-01-3115383230dpl:ParticipatingInterests2025-02-012026-01-3115383230dpl:GroupUndertakingscore:ListedExchangeTraded2025-02-012026-01-3115383230core:ListedExchangeTraded2025-02-012026-01-3115383230dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-02-012026-01-3115383230core:UnlistedNon-exchangeTraded2025-02-012026-01-3115383230dpl:CostSales2024-01-032025-01-3115383230dpl:DistributionCosts2024-01-032025-01-3115383230core:LandBuildings2024-01-032025-01-3115383230core:PlantMachinery2024-01-032025-01-3115383230core:Vehicles2024-01-032025-01-3115383230core:FurnitureFittings2024-01-032025-01-3115383230core:OfficeEquipment2024-01-032025-01-3115383230dpl:AdministrativeExpenses2024-01-032025-01-3115383230core:NetGoodwill2024-01-032025-01-3115383230core:IntangibleAssetsOtherThanGoodwill2024-01-032025-01-3115383230dpl:GroupUndertakings2024-01-032025-01-3115383230dpl:ParticipatingInterests2024-01-032025-01-3115383230dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-032025-01-3115383230core:ListedExchangeTraded2024-01-032025-01-3115383230dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-032025-01-3115383230core:UnlistedNon-exchangeTraded2024-01-032025-01-3115383230core:NetGoodwill2026-01-3115383230core:IntangibleAssetsOtherThanGoodwill2026-01-3115383230core:LandBuildings2026-01-3115383230core:PlantMachinery2026-01-3115383230core:Vehicles2026-01-3115383230core:FurnitureFittings2026-01-3115383230core:OfficeEquipment2026-01-3115383230core:AfterOneYear2026-01-3115383230core:WithinOneYear2026-01-3115383230core:ListedExchangeTraded2026-01-3115383230core:UnlistedNon-exchangeTraded2026-01-3115383230core:ShareCapital2026-01-3115383230core:SharePremium2026-01-3115383230core:RevaluationReserve2026-01-3115383230core:OtherReservesSubtotal2026-01-3115383230core:RetainedEarningsAccumulatedLosses2026-01-3115383230core:NetGoodwill2025-01-3115383230core:IntangibleAssetsOtherThanGoodwill2025-01-3115383230core:LandBuildings2025-01-3115383230core:PlantMachinery2025-01-3115383230core:Vehicles2025-01-3115383230core:FurnitureFittings2025-01-3115383230core:OfficeEquipment2025-01-3115383230core:AfterOneYear2025-01-3115383230core:WithinOneYear2025-01-3115383230core:ListedExchangeTraded2025-01-3115383230core:UnlistedNon-exchangeTraded2025-01-3115383230core:ShareCapital2025-01-3115383230core:SharePremium2025-01-3115383230core:RevaluationReserve2025-01-3115383230core:OtherReservesSubtotal2025-01-3115383230core:RetainedEarningsAccumulatedLosses2025-01-3115383230core:NetGoodwill2024-01-0215383230core:IntangibleAssetsOtherThanGoodwill2024-01-0215383230core:LandBuildings2024-01-0215383230core:PlantMachinery2024-01-0215383230core:Vehicles2024-01-0215383230core:FurnitureFittings2024-01-0215383230core:OfficeEquipment2024-01-0215383230core:AfterOneYear2024-01-0215383230core:WithinOneYear2024-01-0215383230core:ListedExchangeTraded2024-01-0215383230core:UnlistedNon-exchangeTraded2024-01-0215383230core:ShareCapital2024-01-0215383230core:SharePremium2024-01-0215383230core:RevaluationReserve2024-01-0215383230core:OtherReservesSubtotal2024-01-0215383230core:RetainedEarningsAccumulatedLosses2024-01-0215383230core:AfterOneYear2025-02-012026-01-3115383230core:WithinOneYear2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:CostValuation2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3115383230core:Non-currentFinancialInstrumentscore:CostValuation2026-01-3115383230core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-01-3115383230core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-01-3115383230core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-01-3115383230core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-01-3115383230core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-01-3115383230core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-01-3115383230core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-01-3115383230core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-01-3115383230core:Non-currentFinancialInstrumentscore:CostValuation2025-01-3115383230core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-3115383230core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-3115383230core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-3115383230core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-3115383230core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-3115383230core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-3115383230core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-3115383230core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-3115383230bus:Director12025-02-012026-01-3115383230bus:Director22025-02-012026-01-31

LIR THERAPEUTICS LIMITED

Registered Number
15383230
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2026

LIR THERAPEUTICS LIMITED
Company Information
for the year from 1 February 2025 to 31 January 2026

Directors

HANLON, Killian, Dr
O'BRIEN, Hugh, Dr

Registered Address

3rd Floor 1 Ashley Road
Altrincham
WA14 2DT

Registered Number

15383230 (England and Wales)
LIR THERAPEUTICS LIMITED
Balance Sheet as at
31 January 2026

Notes

2026

2025

£

£

£

£

Fixed assets
Tangible assets3156,66570,475
156,66570,475
Current assets
Debtors4211,13084,743
Cash at bank and on hand1,037,2801,940,537
1,248,4102,025,280
Creditors amounts falling due within one year5(25,266)(41,204)
Net current assets (liabilities)1,223,1441,984,076
Total assets less current liabilities1,379,8092,054,551
Net assets1,379,8092,054,551
Capital and reserves
Called up share capital22
Other reserves2,225,0002,225,000
Profit and loss account(845,193)(170,451)
Shareholders' funds1,379,8092,054,551
The financial statements were approved and authorised for issue by the Board of Directors on 2 September 2026, and are signed on its behalf by:
HANLON, Killian, Dr
Director
Registered Company No. 15383230
LIR THERAPEUTICS LIMITED
Notes to the Financial Statements
for the year ended 31 January 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services.
Defined contribution pension plan
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to the income statement in the period to which they relate.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Plant and machinery4
Office Equipment4
Government grants or assistance
Grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received. A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.
2.Average number of employees

20262025
Average number of employees during the year62
3.Tangible fixed assets

Plant & machinery

Office Equipment

Total

£££
Cost or valuation
At 01 February 2572,9323,83176,763
Additions110,3154,337114,652
At 31 January 26183,2478,168191,415
Depreciation and impairment
At 01 February 255,9902986,288
Charge for year26,9981,46428,462
At 31 January 2632,9881,76234,750
Net book value
At 31 January 26150,2596,406156,665
At 31 January 2566,9423,53370,475
4.Debtors: amounts due within one year

2026

2025

££
Other debtors209,73978,053
Prepayments and accrued income1,3916,690
Total211,13084,743
5.Creditors: amounts due within one year

2026

2025

££
Trade creditors / trade payables17,64826,482
Taxation and social security-9,792
Other creditors5,1932,878
Accrued liabilities and deferred income2,4252,052
Total25,26641,204
At the balance sheet date, the Company owed £256 (2025: £311) to the directors and this amount is included within Other creditors. The loan is unsecured, interest free and repayable on demand.
6.Operating lease commitments
Minimum lease payments under non-cancellable operating leases due within one year total £11,283 (2024: £3,893).
7.Further information regarding the company's financial position
Included in other reserves are Convertible Loan Notes totaling £2,225,000 (2024: £2,225,000). The notes are unsecured, subordinated to all other creditors and are expected to convert into equity shares upon a future qualifying funding round. Repayment is only triggered on certain events of default and accordingly the directors have classified the instruments as equity.